Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
复制标题
DOI：
10.1016/j.jaad.2016.08.008
复制
发表时间：
2017-01-01
影响因子：
13.8
通讯作者：
Thaci, Diamant
中科院分区：
文献类型：
--
作者：
Blauvelt, Andrew;Reich, Kristian;Thaci, Diamant
背景资料：在CLEAR研究的第4周和第16周，苏金单抗表现出上级乌司奴单抗的疗效，在中度至重度斑块状银屑病受试者中具有相当的安全性。目的：比较苏金单抗和乌司奴单抗使用超过52周的疗效和安全性。方法：分析来自CLEAR的52周数据，CLEAR是一项随机、双盲、3b期研究。结果：在676例随机化受试者中，在第52周时，在PSSIA面积和严重程度指数（PASI 90）改善>= 90%的受试者比例方面（76% vs 61% [P
Background: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis.Objective: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks.Methods: Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study.Results: Among 676 randomized subjects, secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of subjects with >= 90% improvement in Psoriasis Area and Severity Index (PASI 90) (76% vs 61% [P